Core Viewpoint - The board of Aurite Pharmaceutical Co., Ltd. has approved a share repurchase plan to buy back shares through centralized bidding, with a budget of 60 million to 120 million yuan for the purpose of converting the company's convertible bonds [1] Summary by Relevant Sections - **Repurchase Plan Details** - The repurchase amount is set between 60 million and 120 million yuan, with a repurchase period of 12 months [1] - The upper limit for the repurchase price was originally not to exceed 25 yuan per share, adjusted to not exceed 24.71 yuan per share after equity distribution [1] - **Current Repurchase Status** - As of September 30, the company has repurchased a total of 1,746,738 shares, accounting for 0.43% of the total share capital [1] - The total funds paid for the repurchase amount to 35,607,509.68 yuan, with a repurchase price range between 18.83 and 22.59 yuan per share [1]

Report Summary - The report presents the top ten convertible bonds for October 2025, along with an analysis of the issuing companies, including their business profiles, financial performance, and key attractions [13][23][35] Top Ten Convertible Bonds in October 2025 1. Zhongte Convertible Bond - Rating: AAA; 9 - month - end closing price: 112.896 yuan; Conversion premium rate: 85.92%; PE - TTM of the underlying stock: 13.22 [7][13] - Company: A globally leading specialized special - steel material manufacturer with a production capacity of about 20 million tons of special - steel materials per year. It has multiple production and raw - material bases, forming a strategic layout along the coast and rivers [13] - Financials: In 2024, revenue was 109.203 billion yuan (YoY - 4.22%), net profit attributable to shareholders was 5.126 billion yuan (YoY - 10.41%). In H1 2025, revenue was 54.715 billion yuan (YoY - 4.02%), net profit attributable to shareholders was 2.798 billion yuan (YoY + 2.67%) [13] - Key attractions: It is one of the world's most comprehensive special - steel enterprises in terms of variety and specification, with leading cost - control ability and potential for external expansion [14] 2. Shanlu Convertible Bond - Rating: AAA; 9 - month - end closing price: 119.346 yuan; Conversion premium rate: 48.74%; PE - TTM of the underlying stock: 4.08 [7][23] - Company: Mainly engaged in road and bridge construction and maintenance, and also expanding into other fields. It can provide one - stop comprehensive services [23] - Financials: In 2024, revenue was 71.348 billion yuan (YoY - 2.3%), net profit attributable to shareholders was 2.322 billion yuan (YoY + 1.47%). In H1 2025, revenue was 28.575 billion yuan (YoY + 0.26%), net profit attributable to shareholders was 1.029 billion yuan (YoY + 0.89%) [23] - Key attractions: It has the concept of "China - specific valuation", potential for improvement in various aspects under the debt - resolution background, and opportunities from regional infrastructure construction and the Belt and Road Initiative [24] 3. Hebang Convertible Bond - Rating: AA; 9 - month - end closing price: 126.41 yuan; Conversion premium rate: 21.55%; PE - TTM of the underlying stock: - 168.47 [7][35] - Company: With advantages in mineral resources and gas supply, it has completed a basic layout in the chemical, agricultural, and photovoltaic fields [35] - Financials: In 2024, revenue was 8.547 billion yuan (YoY - 3.13%), net profit attributable to shareholders was 31 million yuan (YoY - 97.55%). In H1 2025, revenue was 3.921 billion yuan (YoY - 19.13%), net profit attributable to shareholders was 52 million yuan (YoY - 73.07%) [35] - Key attractions: Its phosphate mines and salt mines have good profit - making potential, and the liquid methionine business is a major profit contributor [36] 4. Aima Convertible Bond - Rating: AA; 9 - month - end closing price: 128.513 yuan; Conversion premium rate: 38.62%; PE - TTM of the underlying stock: 13.41 [7][45] - Company: The leading enterprise in the electric two - wheeled vehicle industry, mainly engaged in R & D, production, and sales of electric two - wheeled vehicles [45] - Financials: In 2024, revenue was 21.606 billion yuan (YoY + 2.71%), net profit attributable to shareholders was 1.988 billion yuan (YoY + 5.68%). In H1 2025, revenue was 13.031 billion yuan (YoY + 23.04%), net profit attributable to shareholders was 1.213 billion yuan (YoY + 27.56%) [45] - Key attractions: It may benefit from government subsidies, new national standards, and potential improvement in gross margin [46] 5. Xingye Convertible Bond - Rating: AAA; 9 - month - end closing price: 120.859 yuan; Conversion premium rate: 29.02%; PE - TTM of the underlying stock: 5.43 [7][54] - Company: One of the first joint - stock commercial banks in China, evolving into a modern financial service group [54] - Financials: In 2024, revenue was 212.226 billion yuan (YoY + 0.66%), net profit attributable to shareholders was 77.205 billion yuan (YoY + 0.12%). In H1 2025, revenue was 110.458 billion yuan (YoY - 2.29%), net profit attributable to shareholders was 43.141 billion yuan (YoY + 0.21%) [54] - Key attractions: It has stable asset quality and scale growth [55] 6. Wentai Convertible Bond - Rating: AA -; 9 - month - end closing price: 128.918 yuan; Conversion premium rate: 20.93%; PE - TTM of the underlying stock: - 23.14 [7][66] - Company: A globally leading semiconductor enterprise adopting the IDM model, providing R & D, manufacturing, and testing services [66] - Financials: In 2024, revenue was 73.598 billion yuan (YoY + 20.23%), net profit attributable to shareholders was - 2.833 billion yuan (YoY - 339.83%). In H1 2025, revenue was 25.341 billion yuan (YoY - 24.56%), net profit attributable to shareholders was 474 million yuan (YoY + 237.36%) [66] - Key attractions: After focusing on the semiconductor business, it benefits from market recovery and has growth potential in the automotive and consumer electronics fields [67] 7. Chongyin Convertible Bond - Rating: AAA; 9 - month - end closing price: 121.778 yuan; Conversion premium rate: 31.87%; PE - TTM of the underlying stock: 5.88 [7][77] - Company: An early local joint - stock commercial bank in the upper reaches of the Yangtze River and Southwest China, with a wide range of business scopes [77] - Financials: In 2024, revenue was 13.679 billion yuan (YoY + 3.54%), net profit attributable to shareholders was 5.117 billion yuan (YoY + 3.8%). In H1 2025, revenue was 7.659 billion yuan (YoY + 7%), net profit attributable to shareholders was 3.19 billion yuan (YoY + 5.39%) [77] - Key attractions: It can benefit from the development of the Chengdu - Chongqing economic circle, has stable asset - scale growth, and effective risk - control strategies [78] 8. Tianye Convertible Bond - Rating: AA +; 9 - month - end closing price: 120.562 yuan; Conversion premium rate: 48.06%; PE - TTM of the underlying stock: 146.42 [7][89] - Company: A leading enterprise in the chlor - alkali chemical industry in Xinjiang, with an integrated circular economy industrial chain [89] - Financials: In 2024, revenue was 11.156 billion yuan (YoY - 2.7%), net profit attributable to shareholders was 68 million yuan (YoY + 108.83%). In H1 2025, revenue was 5.16 billion yuan (YoY - 0.98%), net profit attributable to shareholders was - 9 million yuan (YoY - 228.22%) [89] - Key attractions: It may benefit from the price change of caustic soda and has plans for dividend increase and coal - mine projects [90] 9. Aorui Convertible Bond - Rating: AA -; 9 - month - end closing price: 126.412 yuan; Conversion premium rate: 40.56%; PE - TTM of the underlying stock: 22.72 [7][100] - Company: A company focusing on the R & D, production, and sales of complex APIs and preparations, with leading positions in multiple fields [100] - Financials: In 2024, revenue was 1.476 billion yuan (YoY + 16.89%), net profit attributable to shareholders was 355 million yuan (YoY + 22.59%). In H1 2025, revenue was 822 million yuan (YoY + 12.5%), net profit attributable to shareholders was 235 million yuan (YoY + 24.55%) [100] - Key attractions: It has a growing dealer network, expanding preparation products, and high - quality customer resources [101] 10. Yushui Convertible Bond - Rating: AAA; 9 - month - end closing price: 125.081 yuan; Conversion premium rate: 30.74%; PE - TTM of the underlying stock: 26.93 [7][108] - Company: The largest integrated water supply and drainage enterprise in Chongqing, with a stable monopoly position [108] - Financials: In 2024, revenue was 6.999 billion yuan (YoY - 3.52%), net profit attributable to shareholders was 785 million yuan (YoY - 27.88%). In H1 2025, revenue was 3.519 billion yuan (YoY + 7.16%), net profit attributable to shareholders was 458 million yuan (YoY + 10.06%) [108] - Key attractions: It has a high market share, is expanding business externally, and has effective cost - control measures [109]

Core Points - The company held its first extraordinary general meeting of shareholders on September 26, 2025, with no resolutions rejected [2][3] - The meeting was conducted in accordance with relevant laws and regulations, including the Company Law and the company's articles of association [2][5] - The company approved several key resolutions, including the appointment of the 2025 annual audit firm and the cancellation of the supervisory board [3][21] Group 1: Shareholder Meeting - The meeting was held at the company's administrative building in Zhejiang Province, with a combination of on-site and online voting [2] - The chairman of the board, Mr. Peng Zhien, presided over the meeting, which complied with legal requirements [2][3] - All proposed resolutions were passed, including the appointment of the audit firm and amendments to the company's articles of association [3][4] Group 2: Employee Representative Meeting - The employee representative meeting took place on September 25, 2025, with 98 out of 100 representatives present [9] - The meeting approved the removal of the employee representative supervisor and the election of an employee representative director [10][11] - Mr. Li Jinliang was elected as the employee representative director, serving until the end of the current board's term [11] Group 3: Shareholder Reduction Announcement - Prior to the reduction plan, the company had a total of 406,195,234 shares, with major shareholders holding 41.88% [15] - The reduction plan involved a maximum of 2,176,600 shares, representing 0.54% of the total shares [16] - The reduction was completed, with the major shareholder retaining 7,730,600 shares, or 1.90% of the total [17] Group 4: Board Meeting - The board meeting was held on September 26, 2025, with 8 out of 9 directors present [20] - The board elected Mr. Peng Zhien as the representative director and legal representative of the company [20] - The board also established an audit committee and made adjustments to the organizational structure, eliminating the supervisory board [21][23]

Core Viewpoint - The company announced a share reduction plan by its controlling shareholder, which has been successfully executed, resulting in a decrease in the shareholder's stake in the company [1] Group 1: Share Reduction Details - The controlling shareholder, Tian Tai Bo Rong Investment Partnership (Limited Partnership), plans to reduce its holdings by up to 2.1766 million shares, representing 0.54% of the company's total share capital [1] - As of September 27, 2025, the shareholder has completed the reduction of 2.1766 million shares, leaving them with 7.7306 million shares, which is 1.90% of the total share capital [1] - The actual price range during the reduction period was between 21.90 and 22.85 yuan per share [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-072 债券代码：111021 债券简称：奥锐转债 减持计划的实施结果情况 公司于 2025 年 8 月 30 日披露《奥锐特药业股份有限公司股东减持股份计划 公告》（公告编号：2025-063），天台铂融为公司的员工持股平台，因部分合伙人 自身资金需求，自本公告发布之日起 15 个交易日后的 3 个月内（窗口期不减持）， 天台铂融拟通过集中竞价、大宗交易方式减持公司股份不超过 2,176,600 股，即 不超过公司总股本的 0.54%。 公司实际控制人不参与本次减持。 奥锐特药业股份有限公司 股东减持股份结果公告 本公司董事会、全体董事及相关股东保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 大股东持股的基本情况 本次减持计划实施前，奥锐特药业股份有限公司（以下简称"公司"）的股 份总数为 406,195,234 股，天台铂融投资合伙企业（有限合伙）（以下简称"天 台铂融"）及其一致行动人浙江桐本投资有限公司（以下简称"浙江桐本"）、天 台铂恩投资管理合伙企业（有限合伙 ...

Group 1 - The core point of the article is that Aorite (605116.SH) announced the completion of a share reduction plan by Tiantai Pluton, which involved a reduction of 2.1766 million shares, accounting for 0.54% of the company's total share capital [1] - Following the reduction, Tiantai Pluton still holds 7.7306 million shares, representing 1.90% of the company's total share capital [1]

证券代码：605116 证券简称：奥锐特 公告编号：2025-070 债券代码：111021 债券简称：奥锐转债 1、审议并通过《关于免去公司第三届监事会职工代表监事的议案》 表决结果为：98 票赞成；0 票反对；0 票弃权。 奥锐特药业股份有限公司 关于职工代表大会决议的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、职工代表大会召开情况 奥锐特药业股份有限公司（以下简称"公司"）于 2025 年 9 月 25 日在浙江 省天台县八都工业园区隆兴路 1 号公司行政楼会议室以现场结合视频通讯方式 召开职工代表大会。本次大会应到职工代表 100 人，实到 98 人。本次会议的召 开符合《公司法》和《公司章程》的有关规定。 二、职工代表大会审议情况 经全体与会职工代表民主讨论，作出如下决议： 奥锐特药业股份有限公司董事会 2025 年 9 月 27 日 附件： 李金亮先生，1972 年生，中国国籍，无境外永久居住权，博士研究生学历。 国家万人计划专家，上海市领军人才，上海市优秀技术带头人；曾获得上海市 青年科技杰出贡献奖 ...

证券代码：605116 证券简称：奥锐特 公告编号：2025-069 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 2025年第一次临时股东大会决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 (一)股东大会召开的时间：2025 年 9 月 26 日 (二)股东大会召开的地点：浙江省天台县八都工业园区隆兴路 1 号公司行政大楼 会议室 (四)表决方式是否符合《公司法》及《公司章程》的规定，大会主持情况等。 本次股东大会由公司董事会召集，公司董事长彭志恩先生主持。本次会议以 现场和网络投票相结合的方式对股东大会通知中列明的事项进行了投票表决，表 决方式符合《中华人民共和国公司法》《上海证券交易所上市公司股东大会网络 投票实施细则》及《奥锐特药业股份有限公司章程》等有关法律、法规的规定。 (五)公司董事、监事和董事会秘书的出席情况 二、 议案审议情况 重要内容提示： 本次会议是否有否决议案：无 一、 会议召开和出席情况 (三)出席会议的普通股股东和恢复表决权的优先股股东及其持有股份情况： | 1、出席 ...

国浩律师（杭州）事务所 关于 奥锐特药业股份有限公司 2025 年第一次临时股东大会 法律意见书 地址：杭州市上城区老复兴路白塔公园 B 区 2 号、15 号国浩律师楼 邮编：310008 Grandall Building, No.2＆No.15, Block B, Baita Park, Old Fuxing Road, Hangzhou, Zhejiang 310008, China 电话/Tel: (+86)(571) 8577 5888 传真/Fax: (+86)(571) 8577 5643 电子邮箱/Mail：grandallhz@grandall.com.cn 网址/Website：http://www.grandall.com.cn 二零二五年九月 奥锐特 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 国浩律师（杭州）事务所 关 于 奥锐特药业股份有限公司 本所律师仅根据本法律意见书出具日以前发生或存在的事实及有关法律、行 1 奥锐特 2025 年第一次临时股东大会法律意见书 国浩律师（杭州）事务所 2025 年第一次临时股东大会 法律意见书 致：奥锐特药业股份有限公司 ...

1、审议通过《关于选举代表公司执行公司事务董事的议案》 证券代码：605116 证券简称：奥锐特 公告编号：2025-071 债券代码：111021 债券简称：奥锐转债 奥锐特药业股份有限公司 第三届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 奥锐特药业股份有限公司（以下简称"公司"）第三届董事会第十六次会议 于 2025 年 9 月 26 日在公司会议室以现场结合通讯方式召开。根据公司《董事会 议事规则》的有关规定，经全体董事同意，本次董事会会议豁免通知时限要求， 本次会议通知于 2025 年 9 月 25 日通过邮件、电话通知等方式向全体董事及高级 管理人员发出。本次会议由董事长彭志恩召集并主持，应到董事 9 人，实到董事 8 人。 本次会议的通知、召开、表决程序符合《中华人民共和国公司法》《奥锐特 药业股份有限公司章程》以及相关法律、法规的有关规定，会议形成的决议合法 有效。 二、董事会会议审议情况 鉴于李金亮先生辞去公司董事及战略委员会相关职务，经公司职工代表大会 ...